Get the Stockscreener App
7.49
0.13%
-0.010
After Hours:
7.49
Bioventus Inc stock is traded at $7.49, with a volume of 231.39K.
It is down -0.13% in the last 24 hours and down -22.38% over the past month.
Bioventus Inc is a medical technology company. The company is engaged in developing and commercializing clinically differentiated treatments that engage and enhance the body's natural healing process. It offers a diverse portfolio of products to serve physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine and neurosurgery. Its portfolio of products is grouped into three verticals based on clinical use: Pain Treatments, Surgical Solutions, and Restorative Therapies. Geographical presence is in the United States which derives key revenue, and International markets.
See More
Previous Close:
$7.50
Open:
$7.64
24h Volume:
231.39K
Relative Volume:
0.74
Market Cap:
$512.05M
Revenue:
$555.06M
Net Income/Loss:
$-39.48M
P/E Ratio:
-12.48
EPS:
-0.6
Net Cash Flow:
$29.05M
1W Performance:
-3.23%
1M Performance:
-22.38%
6M Performance:
-42.25%
1Y Performance:
+74.59%
1-Day Range:
$7.445
$7.78
1-Week Range:
$7.33
$7.98
52-Week Range:
$3.90
$14.38
Bioventus Inc Stock (BVS) Company Profile
Name
Bioventus Inc
Sector
Industry
Phone
(919) 474-6700
Address
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Compare BVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BVS
Bioventus Inc
|
7.49 | 512.05M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-17-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Dec-07-23 | Upgrade | Canaccord Genuity | Hold → Buy |
| Aug-09-23 | Upgrade | Craig Hallum | Hold → Buy |
| Nov-22-22 | Downgrade | Craig Hallum | Buy → Hold |
| Nov-09-22 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-22 | Downgrade | JP Morgan | Overweight → Underweight |
| Mar-15-22 | Initiated | Craig Hallum | Buy |
| Nov-15-21 | Resumed | Morgan Stanley | Overweight |
| Nov-10-21 | Resumed | JP Morgan | Overweight |
| Jul-01-21 | Downgrade | Goldman | Buy → Neutral |
| Mar-08-21 | Initiated | Canaccord Genuity | Buy |
| Mar-08-21 | Initiated | Goldman | Buy |
| Mar-08-21 | Initiated | JP Morgan | Overweight |
| Mar-08-21 | Initiated | Morgan Stanley | Overweight |
View All
Bioventus Inc Stock (BVS) Latest News
SEC Form DEFA14A filed by Bioventus Inc. - Quantisnow
Bioventus SVP Katrina Church sells shares for $9,712 - Investing.com Australia
Bioventus CFO Singleton sells $29,333 in stock - Investing.com Australia
Bioventus SVP Katrina Church sells shares for $9,712 By Investing.com - Investing.com South Africa
Bioventus CFO Singleton sells $29,333 in stock By Investing.com - Investing.com South Africa
Bioventus SVP sells shares worth $22,392 By Investing.com - Investing.com India
Bioventus SVP sells shares worth $22,392 - Investing.com
Bioventus Executives Sell Shares to Cover Taxes - TradingView
Bioventus Inc. (NYSE:BVS) Shares Acquired by Vanguard Group Inc. - Defense World
KLP Kapitalforvaltning AS Acquires Shares of 7,100 Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus ($BVS) Is Paying a $15.2M Settlement to Investors — Here’s How to Get Your Share - TradingView
Intramedullary Nail Market size to worth USD 1,537 Million by 2032, says Coherent Market Insights - GlobeNewswire Inc.
Commonwealth Equity Services LLC Raises Stock Holdings in Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus Inc.'s (NASDAQ:BVS) institutional investors lost 9.6% over the past week but have profited from longer-term gains - simplywall.st
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
HighTower Advisors LLC Increases Position in Bioventus Inc. (NYSE:BVS) - Defense World
(BVS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Ensign Group Invests in Growth With New Facility Acquisitions - TradingView
Canaccord maintains Bioventus stock with $15 target, bullish outlook By Investing.com - Investing.com Australia
Canaccord maintains Bioventus stock with $15 target, bullish outlook - Investing.com
Here's Why Bioventus (BVS) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Bone Growth Stimulator Market Is Booming Worldwide | Orthofix Medical Inc., Medtronic, Zimmer Biomet, Bioventus Inc - openPR.com
Charles Schwab Investment Management Inc. Grows Position in Bioventus Inc. (NYSE:BVS) - Defense World
Bioventus CFO Mark Leonard sells $53,639 in stock By Investing.com - Investing.com Australia
Bioventus CFO Mark Leonard sells $53,639 in stock - Investing.com India
(BVS) Proactive Strategies - news.stocktradersdaily.com
Bioventus (BVS) Q4 Earnings and Revenues Surpass Estimates - MSN
Bioventus SVP Katrina Church sells shares worth $9,925 By Investing.com - Investing.com Australia
Bioventus SVP Anthony D’Adamio sells $25,496 in stock - Investing.com India
Bioventus SVP Katrina Church sells shares worth $9,925 - Investing.com India
Europe Viscosupplementation Market Projected To Witness Substantial Growth, 2025-2032: Sanofi S.A., Bioventus - EIN News
Bioventus (NYSE:BVS) Receives “Buy” Rating from Canaccord Genuity Group - Defense World
Bioventus (BVS) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
How To Trade (BVS) - news.stocktradersdaily.com
Earnings call transcript: Bioventus Q4 2024 beats revenue forecast, stock surges - Investing.com Australia
Bioventus Earnings Call: Strong Growth & 2025 Outlook - TipRanks
Bioventus Inc. (NASDAQ:BVS) Q4 2024 Earnings Call Transcript - Insider Monkey
Bioventus: Strong Financial Performance and Strategic Growth Drive Buy Rating - TipRanks
Bioventus Full Year 2024 Earnings: Beats Expectations - Yahoo
Bioventus Faces Potential Stock Dilution Risk Amid Resale of 35 Million Shares - TipRanks
Bioventus Inc (BVS) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Debt ... - Yahoo Finance
Bioventus Inc (BVS) Q4 2024 Earnings Call Highlights: Strong Rev - GuruFocus.com
Bioventus Reports Strong 2024 Financial Performance - TipRanks
Bioventus: Q4 Earnings Snapshot - mySA
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results - OrthoSpineNews
Bioventus: A Medical Technology Company on the Move - RagingBull
Medical Device Firm Bioventus Stock Jumps On Upbeat 2025 Outlook, Cuts Debt By $48 Million - Benzinga
Bioventus Shares Rise After Improved 4Q - MarketWatch
Korn Ferry Posts Better-Than-Expected Earnings, Joins Bioventus, Endeavour Silver, Vail Resorts And Other Big Stocks Moving Higher On Tuesday - Benzinga
Bioventus Inc Stock (BVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):